Boots owner ‘closing in on sale to Canada’s Weston family for $9bn’

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-10-01 • Permanent link

Rumors are swirling around a potential sale of Boots, the UK's largest pharmacy chain, to Canada's Weston family for a whopping $9 billion. The deal, which is reportedly closing in, would mark a significant return to the UK for the Weston family, who sold their Selfridges department store for £4 billion in 2022. Market analysts are already weighing in on the potential impact of the sale, with some speculating that it could lead to a shake-up in the UK's pharmacy sector. As the news spreads, investors are holding their breath, waiting to see how this deal will play out.

The Weston family's acquisition of Boots would have far-reaching implications for consumers, who would likely see changes in the way they shop for their medications and healthcare services. With Boots operating over 2,500 stores across the UK, the sale could lead to a reduction in competition, potentially driving up prices and limiting access to certain products. Moreover, the Weston family's ownership of Selfridges, a luxury department store, could also lead to increased consolidation in the retail sector, further concentrating market power in the hands of a few large players.

Historically, the UK's pharmacy sector has been shaped by a mix of public and private ownership. Since the 1990s, the sector has undergone significant consolidation, with several major players emerging. However, the Weston family's acquisition of Boots would be a significant development, potentially altering the dynamics of the sector. According to experts, the sale could also have implications for the NHS, which relies heavily on Boots for its pharmacy services.

As the sale of Boots to the Weston family nears completion, investors are eagerly awaiting the next move. The deal is expected to be finalized in the coming months, pending regulatory approvals. With the UK's pharmacy sector on high alert, one thing is certain: the outcome of this deal will have far-reaching consequences for consumers, investors, and the broader economy.